DALLAS, Oct. 26, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring healthcare company MedaSorb Technologies Corp. (OTCBB:MSBT). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on MedaSorb Technologies Corp. (OTCBB:MSBT) should be of particular interest to other healthcare companies: Baxter International Inc. (NYSE:BAX), Eli Lilly & Company (NYSE:LLY) and Fresenius Medical Care Co. (ADR) (NYSE:FMS).
The full report is available at: http://www.stockpreacher.com/n/MSBT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
MedaSorb Technologies Corp. (MSBT) engages in the development of medical device technologies focused on the treatment of sepsis and other conditions of the blood. The Company is currently in clinical trials in the United States and Europe with its proprietary blood purification device, CytoSorb(TM). The CytoSorb is designed to reduce "cytokine storm" associated with sepsis -- a leading cause of death worldwide.
Message Board Search for MSBT: http://www.boardcentral.com/boards/MSBT
In the report, the analyst notes:
"The Company has manufactured only a few CytoSorb devices for testing purposes, including clinical trials in the United States and Europe. The Company's medical team believes that the CytoSorb device is unparalleled in the effective clearing of cytokines, which are not cleared effectively by today's state-of-the-art dialysis machines.
"Management determined that proceeding with the limited trial in the United States would add approximately one year more to the process of commercialization, and therefore proceeded to obtain regulatory approval in Europe, first, before proceeding toward FDA approval for commercialization of the CytoSorb in the United States. The Company's strategy to market the CytoSorb in an equivalent market potential of Europe began with the submission for CE Marking in July 2007, which in October 2007 was approved by the German Central Ethics Committee for the final stage design of the initial clinical trial."
To read the entire report visit: http://www.stockpreacher.com/n/MSBT
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.